Landauer — Investor Presentation (May 2013)
19 slides from Landauer's investor presentation, May 8, 2013
Slide 1: Landauer, Inc. Investor Presentation May 8, 2013
LANDAUER, INC. Investor Presentation May 8, 2013
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement Some of the information shared here (including, in particular, the section titled “Fiscal 2013 Outlook”) constitutes forward - looking statements that are based on assumptions and involve certain risks and uncertainties . These include the following, without limitation : assu
Slide 3: Fiscal 2013 Second Quarter Highlights
3 Consolidated revenue $37.1 million, $2.0 million below prior year: » Medical Products down $1.8 million due to lower S pherz volume and price » Medical Physics down due to less episodic services Consolidated gross profit $20.0 million, $3.0 million below prior year: - Additional IT Platform de
Slide 4: The Radiation Safety Continuum
Therapeutic / Diagnostic Accessories Information Imaging Physics Therapy Physics Patient Monitoring Occupational Monitoring Consulting Integrated Radiation Safety Solution Existing Services with Penetration Opportunities (1) Complementary Adjacent Products / Services _____________________ (1) Averag
Slide 5: Landauer Strategy Overview
Value Creation Deliver Upside Growth 1. Optimize Core 2.Competitive Growth 3. Strategic Expansion Strategic Priorities Landauer Strategy Overview Strategic Expansion Optimize the Core Competitive Growth New Management/ Structure • Chief Financial Officer Q1’12 • Radiation Measurement Segment Q3‘12
Slide 6: Radiation Measurement Segment
6 Radiation Measurement Segment Optimize the Core ▪ IT System Stabilization: Post Go - Live in Q4 FY2012 ▪ $4.4 million in expense in FY 2013 ▪ Over 8,500 customers now on new web enabled system; versus previously 3,000 customers on 3 - legacy mainframe systems Competitive Growth ▪ Group Purchasing
Slide 7: New IT Platform Enhancement Expenses
7 New IT Platform Enhancement Expenses Depreciation / Steady State / Customer Service / Implementation / Stabilization expenses: ― Total FY 2013 vs. FY 2012 $ 4.4 million increased expense over prior year • Depreciation, additional $2.4 million » Split between COG’s ($1.4 million) and SG&A ($1.0 m
Slide 8: LDR IT Evolution: 2006-2012
8 LDR IT Evolution: 2006 - 2012 Applications (since 2007) Infrastructure (since 2007) • Customer Records - o ver 500M records migrated from IBM legacy system to new IT System platform • Data Center Co - location Strategy – implemented in FY12. Disaster Recovery / Risk Mitigation: total investment to
Slide 9: Military and Emergency Response Market Opportunity
Military and Emergency Response Market Opportunity Expanding application of next generation technology to pursue global military and first responder radiation monitoring markets The U.S. military has now issued orders in excess of $20 million to upgrade its tactical dosimetry capabilities, and d
Slide 10: Network of Activities - Synchronization
10 Network of Activities - Synchronization
Slide 11: Medical Physics Segment
11 Medical Physics Segment Optimize the Core ▪ Profitability Improvement Initiatives: personnel utilization / exiting low margin legacy contracts ▪ Operating Margin of 10 percent year - to - date vs. 6.7 percent full year FY2012 vs. operating income loss in FY2011 Competitive growth ▪ Group Purchasi
Slide 12: Radiation Safety is becoming more complex
Radiation Safety is becoming more complex Assessment Remediation Ongoing Execution Control & Monitor 12 Advanced imaging and treatment choices, healthcare consolidation and tougher regulations and standards are raising the bar for radiation safety
Slide 13: Enterprise Radiation Safety Portal
opes . oti About LANDAUER werifii Enterprise Radiation Safety Portal ContactUs “Medical ysis insights with impact oe Poser? LANDAUER veDicaL PVs | 13
Slide 14: Medical Products Segment
14 Medical Products Segment Changing market dynamics Reorganized Leadership and Sales personnel/ structure/ processes in the fiscal quarter » CEO – twenty years of medical device product development experience » V.P. Sales – ten years of medical device experience Acquisition » Acquired the ass
Slide 15: IZI Medical Products - Market Map
15 IZI Medical Products - Market Map Spherz Radiation Therapy
Slide 16: FY 2013 Outlook vs. FY 2012 Actual
16 FY 2013 Outlook vs. FY 2012 Actual Non - Cash Stock Based Compensation Previous Revised Guidance Guidance – FY 2013 Forecast $3.3M $2.7M – FY 2012 Actual $2.4M – Delta $0.9M $0.3M
Slide 17: Fiscal Year 2013 Outlook - Updated
FY 2013 Outlook Updated 17 Fiscal Year 2013 Outlook - Updated ▪ Expected Revenue $ 150 to $ 155 million, which includes a full fiscal year of contributions from the IZI Medical Products acquisition, versus 10.5 months in fiscal 2012 ▪ Adjusted EBITDA of $51 to $ 53 million ▪ Net Income of $21 to $23
Slide 18: Current Dividend Policy
18 Current Dividend Policy Current Dividend Policy • Board of Directors declared a regular quarterly cash dividend of $0.55 per share for the f irst quarter of fiscal 2013 – This represents an annual rate of $2.20 per share, consistent with fiscal 2012 levels – For the first fiscal quarter, the divi
Slide 19: Questions?
Questions? Investor Presentation May 8, 2013